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INTRODUCTION
AMP-activated protein kinase (AMPK) is an evolutionary conserved energy sensor which functions to maintain energy homeostasis through coordinating effective metabolic responses to reduced energy availability 1, 2 . Low-energy conditions under various pathophysiological settings (e.g. nutrient deprivation, physical activity, ischemia), characterized by elevated AMP:ATP or ADP:ATP ratios, trigger AMPK activation. Once activated, AMPK promotes ATP-producing, catabolic pathways and decreases ATP-consuming, anabolic pathways to restore and maintain cellular ATP at a constant level.
AMPK is a heterotrimeric complex composed of a catalytic α-subunit and two regulatory β and γ subunits. Two to three isoforms exist for each subunit (α1 and α2, β1 and β2, and γ1, γ2, and γ3), giving rise to 12 distinct combinations of the heterotrimeric complexes. In general α1, β1, and γ1 appear to be the ubiquitously expressed isoforms of AMPK. There are cell-and tissue-specific distributions of some isoforms (e.g. exclusive expression of γ3 in skeletal muscle 3, 4 ), and they may target AMPK complexes to particular subcellular locations to phosphorylate specific substrates 5, 6 . The γ subunits contain four tandem cystathionine β-synthase (CBS) repeats that provide adenine nucleotide binding 7 . AMPK activity increases >100-fold on phosphorylation of a conserved threonine residue within the activation loop (Thr172). Binding of ADP and/or AMP causes conformational changes that favor net Thr172 phosphorylation by the promotion of Thr172 phosphorylation and the inhibition of Thr172 dephosphorylation [8] [9] [10] . In addition, the binding of AMP (but not ADP) further promotes AMPK activity by >10-fold by allosteric activation 8 . The major upstream kinase catalyzing AMPKα Thr172 phosphorylation in most mammalian cells/tissues, including skeletal muscle and liver, is the tumor suppressor kinase LKB1 11 . In some cell types, Thr172 can be phosphorylated in a Ca 2+ -mediated process catalyzed by Ca 2+ /calmodulin-dependent protein kinase kinases 12 .
AMPK is considered an attractive therapeutic target for metabolic disorders since AMPK activation brings about metabolic responses anticipated to counteract the metabolic abnormalities associated with obesity, insulin resistance, and type 2 diabetes 13,14 . Indeed several compounds, which can be divided into three categories 12 , have been reported to activate AMPK and elicit metabolic effects in cellular and pre-clinical studies. The first class comprises indirect activators which, through inhibition of mitochondrial respiration and eventual suppression of ATP synthesis, increase cellular AMP:ATP or ADP:ATP ratios (e.g. metformin, resveratrol) 15 .
The second class includes pro-drugs converted to AMP analogs inside the cells, and the most well characterized and commonly used compound is 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) 16, 17 . The allosteric activators, binding to a site located between the α-subunit kinase domain and the β-subunit carbohydrate binding module (CBM) termed "allosteric drug and metabolite (ADaM)" site, constitute the third class. The first compound identified through a high-throughput screen 18 as an allosteric AMPK activator is A769662, a thienopyridone that preferentially activates β1-containing complexes 19 . More recently 991 was developed, a cyclic benzimidazole which binds AMPK 10 times tighter than A769662 in cellfree assays 20 and activates both β1-and β2-containing complexes (with a higher affinity to the β1 complexes) 4, 21 . It has been reported that A769662 causes several off-target effects, for example in isolated mouse skeletal muscle when used at high concentration 22 and also in other cells/tissues 23, 24 and was reported to have poor oral availability 18 . Notably, an emerging new generation of ADaM site-binding compounds, including MK-8722 and PF-739, have been shown to be effective in reversing elevated blood glucose concentrations in rodents and nonhuman primates through activation of AMPK in vivo 25, 26 .
It is well established that AMPK elicits a plethora of acute metabolic responses through phosphorylation of serine residues surrounded by the well characterized recognition motif 27 .
There has been much effort into the identification of AMPK substrates, and several targeted and untargeted proteomics studies have been performed [28] [29] [30] [31] [32] , which led to a mechanistic understanding of AMPK-mediated metabolic responses and the discovery of new roles for AMPK beyond conventional metabolic regulation (e.g. cell cycle, autophagy). Growing evidence suggests that in the long-term AMPK promotes metabolic reprogramming via effects on gene expression at least partly through regulation of specific transcription factors and transcriptional co-activators 1, 12 .
In the current study we initially performed a comprehensive transcriptomic profiling in wild-type (WT) and AMPK-deficient (AMPKα1/α2 double knockout (AMPK KO)) mouse embryonic fibroblasts (MEF) and primary hepatocytes treated with AICAR and 991, which led to the identification of distinct compound-dependent gene expression signatures and to the discovery of several AMPK-regulated genes. Gene set enrichment and pathway analyses prompted us to hypothesize that the transcription factor EB (TFEB) is a potential key transcription factor responsible for AMPK-mediated gene expression. We found that expression of Flcn, a gene which encodes the tumor suppressor folliculin (FLCN), was abolished in both AMPK KO and TFEB/TFE3 double KO MEF and the promoter activity of Flcn was profoundly reduced when the putative TFEB-binding site was mutated. Finally, we found that AMPK activates TFEB through promotion of dephosphorylation and nuclear translocation independently of mTOR signaling.
RESULTS

Whole-genome transcriptome profiling revealed distinct gene expression profiles in response to AMPK activators in MEF and primary hepatocytes
To identify genes and pathways regulated in an AMPK-dependent mechanism, we performed a whole-genome transcriptome profiling using microarray technology (Affymetrix Mouse GeneChips MEF and mouse primary hepatocytes were treated with vehicle, 991 or AICAR at the indicated concentrations for 4 hours. Following treatment, one set of the samples was subjected to transcriptome profiling and the other set was used for immunoblotting to assess the effect of compounds on AMPK activity. We initially confirmed by immunoblot analysis that treatment of WT MEF with 991 (10 µM) or AICAR (2 mM) resulted in an increase in phosphorylation of AMPK (Thr172) and its bona fide substrates acetyl CoA carboxylase (ACC) (Ser79) and raptor (Ser792) (Fig. 1A) . Similar results were obtained when WT mouse primary hepatocytes were treated with 991 (3 µM) or AICAR (300 µM) (Fig. 1B) . Notably, although treatment with 991
or AICAR resulted in a comparable elevation of ACC phosphorylation in both MEF and hepatocytes, 991-induced raptor phosphorylation was higher in MEF but lower in hepatocytes compared to AICAR (Fig. 1A, B) . As previously demonstrated [33] [34] [35] , there was no detectable phosphorylation of AMPK, ACC and raptor in vehicle-and 991-/AICAR-treated AMPK KO MEF and hepatocytes (Fig. 1A, B) . Taken together, we validated a complete ablation of AMPK activity in both AMPK KO MEF and hepatocytes, and observed differential responses in commonly used surrogate markers for cellular AMPK activity (i.e. phosphorylation of ACC and raptor) following the treatment with 991 or AICAR.
We next performed a whole transcriptome profiling using Affymetrix MOE430 arrays.
A principal component analysis (PCA) was conducted for initial evaluation of data quality and assessment of the effect of genotype and treatment on the transcriptome ( Supplementary Fig.   1A , B). In MEF the PCA clarified that genotype was the primary factor responsible for variance, followed by treatment, and that globally AICAR caused a greater transcriptional response compared to that induced by 991. It also implied that 991 induced a rather limited, but potentially more specific transcriptional responses compared to AICAR. In contrast, in primary hepatocytes, treatment was the main cause of variance, followed by a lower variance explained by genotype. AICAR consistently produced a much greater response than that driven by 991.
These observations were well corroborated by the hierarchical clustering ( Fig. 2A, B ).
Identification and validation of AMPK-dependent genes and pathways
To clarify genes specifically regulated following AMPK activation, we first selected genes by pairwise differential analysis of MEF and primary hepatocytes treated with AICAR or 991 as compared to vehicle. P-values were corrected for multiple testing using the false-discovery rate (Fig. 3A, B) . Altogether, these findings suggest that 991 elicits much more AMPK-specific transcriptional responses compared to AICAR, an observation which is corroborated by the results of PCA (Supplementary Fig. 1 ) and hierarchical clustering ( Fig. 2A,   B ).
To illuminate the pathways regulated by AMPK, we performed a gene ontology analysis on the genes differentially expressed upon 991 treatment in primary hepatocytes and MEF using the Database for Annotation, Visualization and Integrated Discovery (DAVID) program 37, 38 ( Fig. 4 A, B) . This analysis revealed a commonly shared signature of biological/metabolic pathways (e.g. lysosomes) observed in both cell types, as well as additional cell type-specific pathways such as ErbB signaling, sphingolipid metabolism and adipocytokine signaling for primary hepatocytes, and steroid biosynthesis and biosynthesis of antibiotics for MEF, respectively (Fig. 4A, B 
991-/AICAR-stimulated Flcn expression is AMPK-TFEB/TFE3 dependent
To shed light on the mechanism by which AMPK modulates expression of specific genes, we next conducted an in silico analysis to identify potential transcription factors responsible for the AMPK-dependent responses upon compound treatment. To this end, we performed a search for correlation in expression between the 991-responsive transcripts identified in MEF (184 targets) and hepatocytes (670 targets), and the expression of potential upstream regulators using the Ingenuity Pathway Analysis (IPA) tool 39 ( Table 1 ). The IPA revealed that there were around 10 candidates and only two of these, sterol regulatory element binding protein 1 (SREBP1) and TFEB, were identified in both MEF and hepatocytes (Table 1) . SREBP1 is a master transcriptional regulator of lipid synthesis and its activity is known to be regulated by AMPKmediated phosphorylation 40 . TFEB and TFE3 are members of the micropthalmia (MiT/TFE) family of HLH-leucine zipper transcription factors that play an important role in the control of cell and organismal homeostasis through regulating lysosomal biogenesis and autophagy 41 .
TFEB is also known to be indirectly regulated by AMPK in the control of lineage specification in embryoid bodies 42 . Interestingly, it was recently reported that TFEB/TFE3 regulate energy metabolism, although the underlying mechanism remains elusive 43, 44 . Among the genes regulated specifically in an AMPK-dependent manner (Fig. 4C, D (Fig. 5A ).
We confirmed that the increased levels of Flcn mRNA were due at least partly to enhanced gene transcription, since pre-mRNA levels of Flcn were also significantly elevated in response to 991 and AICAR treatment (Supplementary Fig. 2A, B) . Moreover, we confirmed that the elevated levels of Flcn transcripts were translated into an increase in FLCN protein levels in a time-and AMPK-dependent manner in response to 991 or AICAR treatment (Fig. 5B) Supplementary Fig. 2C ). Notably, when the putative TFEB binding site was mutated in the 1200 and 100 bp fragments and the corresponding reporter constructs introduced in WT MEF, 991-induced promoter activity was significantly reduced (Supplementary Fig. 2D ). Taken
together, these results demonstrate that AMPK promotes Flcn transcription through activation of TFEB/TFE3.
AMPK promotes dephosphorylation and nuclear translocation of TFEB independently of mTOR
It has been reported that the transcriptional activity of TFEB is coupled to its subcellular localization and is regulated by reversible phosphorylation. We thus wanted to determine if AMPK-induced activation of TFEB occurs as a consequence of its dephosphorylation and nuclear localization. To test this hypothesis, we treated WT and AMPK KO MEF with 991 or AICAR for 4 hours and prepared cytoplasmic and nuclear fractions followed by immunoblot analysis (Fig. 6A) . ACC was only detected in the cytoplasm as anticipated and its phosphorylation was increased (~2 fold) after treatment with the compounds. In WT MEF both 991 and AICAR similarly decreased and increased TFEB levels in cytoplasmic and nuclear fractions, respectively, whereas the levels of TFEB were not altered in both fractions upon treatment with 991 or AICAR compared to control (vehicle) in AMPK KO MEF. Notably, both compound treatments resulted in a marked increase in a faster-migrating form of TFEB, indicative of TFEB dephosphorylation, in the nuclear fraction in WT but not in AMPK KO MEF (Fig. 6A ). To examine if the faster migration of TFEB was associated with dephosphorylation, we generated a phospho-specific antibody against Ser (S)142, one of the key phosphorylation sites impacting cellular localization and activity of TFEB 48 . We verified and confirmed the specificity of the phospho-S142 TFEB antibody by immunoblotting using recombinant WT and non-phosphorylatable Ala (A) mutant form (S142A) of N-terminus Flagtagged mouse TFEB (Fig. 6B ). Given that mTOR has been demonstrated to act as a key upstream regulator of TFEB and that AMPK is known to modulate mTOR activity, we also wanted to address if AMPK-mediated dephosphorylation and nuclear localization of TFEB were dependent on mTOR (Fig. 6C) . Consistent with the results shown in Fig. 6A , both 991
and AICAR treatment (for 1 and 4 hours) resulted in a downward band-shift of total TFEB in WT, which was associated with a decrease in S142 phosphorylation. In contrast, compound treatment had no effect on both band-shift and S142 phosphorylation in AMPK KO MEF ( of TFEB in both WT and AMPK KO MEF (Fig. 6C) . It has previously been demonstrated that nutrient-induced S142 phosphorylation was resistant to Rapamycin but sensitive to a novel class of mTOR inhibitor (Torin) targeting catalytic site of mTOR 48 . Torin (5 or 10 nM for 1 or 4 hours) inhibited mTOR activity (i.e. ablated phosphorylation of p70 S6K and S6RP) to a similar degree compared to Rapamycin. Of note, Torin treatment (10 nM, 4 hours) caused a modest downward band-shift and dephosphorylation (S142) of TFEB, although this was not AMPKdependent since it was observed in both WT and AMPK KO MEF (Fig. 6D ).
We next wanted to determine if the AMPK-dependent and mTOR-independent dephosphorylation and nuclear enrichment of TFEB in response to AMPK activators could also be observed in mouse primary hepatocytes (Fig. 7A, B) . As anticipated, treatment of hepatocytes with AMPK activators (991, AICAR, and also C13, a recently identified α1-selective AMPK activator 34, 49 ) for 1 or 4 hours robustly increased phosphorylation of AMPK and ACC in WT, which was totally ablated in AMPK KO hepatocytes (Fig. 7A ). AICAR and C13, but not 991, potently reduced phosphorylation of p70 S6K and S6RP in an AMPKdependent mechanism, except that C13 (4 hours) displayed an AMPK-independent inhibition of mTOR. In control (vehicle-treated) hepatocytes, total TFEB appeared as doublets in WT, whereas in AMPK KO hepatocytes TFEB band was fainter and smeary compared to WT.
Consistent with our observations using MEF ( hepatocytes. We also observed that treatment of WT hepatocytes with the AMPK activators decreased and increased TFEB levels in cytoplasmic and nuclear fractions, respectively (data not shown). Of note, we attempted to assess TFEB S142 phosphorylation, however it was not detectable most likely due to the low abundance of total TFEB in mouse primary hepatocytes (data not shown). In line with the observations in MEF ( The control and exercise groups comprised a mixed population of WT and knockout fish, to ensure consistency between the experimental groups. The control group was placed in the swim tunnel and subjected to a low flow speed (5 cm/s) for 3 hours. For the exercise group, an acclimatization period of 20 min at a low flow speed (5 cm/s) was followed by a gradual increase of water velocity up to 80% of maximum speed capacity (i.e. 60 cm/s for this cohort of fish), which was maintained for approximately 2 hours. Notably, the maximum speed of the fish, defined as the maximum sustainable swimming speed, was determined in a previous grouped endurance test following the existing guidelines 50 . Subsequently, the skeletal muscles were rapidly extracted to avoid AMPK activation due to cellular stress (e.g. hypoxia). The loss of expression/function of AMPK in the knockout fish was assessed by immunoblotting, which confirmed the absence of expression and activity of the AMPK catalytic subunits (Fig. 8C) . We confirmed that an acute bout of exercise increased AMPK activity as judged by an increase in phosphorylation of AMPK and ACC in WT muscle (Fig. 8C) . Finally, we compared by qPCR the levels of flcn and fnip2, the paralogue of fnip1. The results showed an increased level of expression of both genes after physical exercise in WT zebrafish, and that this increase was significantly decreased in prkaa1/prkaa2-deficient zebrafish (Fig. 8D) . Taken together, these data suggest that exercise increases the activity of AMPK in zebrafish, which is associated with an increase in flcn and fnip2 expression that is at least in part mediated through AMPK.
DISCUSSION
It is well documented that AMPK not only elicits a plethora of acute metabolic responses, but also promotes metabolic reprogramming by modulating gene expression through regulation of specific transcription factors and transcriptional co-activators 12,27,51 . In the current study, we performed whole-genome transcriptome profiling in AMPK-intact or -deficient mouse embryonic fibroblasts and hepatocytes. We identified several new AMPK-dependent/-regulated genes and pathways that are differentially regulated in a cell type-and a compound-specific manner. The major finding of this study was that we found TFEB, a transcription factor and emerging regulator of lysosomal biogenesis/autophagy 52 , as one of the key mediators of AMPK-dependent transcriptional responses.
We performed transcriptome profiling using two different AMPK activators (AICAR and 991), known to target distinct regulatory sites/mechanisms. AICAR is a valuable and the most commonly used pharmacological AMPK activator, which significantly contributed to uncover critical metabolic functions of AMPK for decades [53] [54] [55] . In recent years, with the development and availability of genetic technologies/tools (i.e. AMPK KO models), as well as highly-specific AMPK activators targeting ADaM site, the specificity of AICAR has been questioned. Several studies have reported AICAR's off-target effects 17 , for example on AMPregulated enzymes such as fructose 1,6-bisphosphatase, a key regulator for hepatic gluconeogenesis 56, 57 . To our knowledge, this is the first study investigating the effect of AICAR on genome-wide gene expression employing AMPK-deficient cell models to dissect AMPKdependent/-independent effects. It was striking to find out that the vast majority of the transcripts were significantly altered with AICAR in the absence of functional AMPK. This implied that previously claimed signaling, cellular, as well as physiological effects induced by AICAR may not be mediated through AMPK (unless its off-target effects were ruled out using AMPK KO models as a control). In contrast, 991 exhibited nearly exclusive specificity for targeting AMPK in both MEF and hepatocytes consistent with the specificity of this compound that we showed in vitro (cell-free) in our previous study 4 . 991 activates both β1-and β2-containing complexes (with higher affinity to the β1 complexes), thus it acts as a pan/total AMPK activator. Given that isoform-specific AMPK activators have recently been identified 34, 58 , it would be of interest to elucidate isoform-specific gene responses and metabolic programming.
The cellular localization and activity of TFEB are primarily regulated by its phosphorylation status. Two serine residues, S142 and S211, in the TFEB have mainly been proposed to play a key role in determining its subcellular localization 48, 52 . When both sites are phosphorylated, TFEB is kept inactive in the cytosol, while mutation of either S142 or S211 to non-phosphorylatable alanine residue rendered TFEB constitutively active through keeping it within the nucleus. mTOR and ERK2 are the main protein kinases known to phosphorylate TFEB under nutrient-rich conditions supplemented cells with conventional cell culture medium) in most cell types. AMPK inhibits mTOR through multiple mechanisms [59] [60] [61] , and it has recently been reported that AMPK controls endolysosomal function through suppression of mTOR and its subsequent regulation of TFEB 42 . Therefore, we initially hypothesized that 991-or AICAR-induced activation of TFEB, via dephosphorylation and nuclear localization, is mediated through the AMPK-dependent inhibition of mTOR. Contrary to our hypothesis, we observed that acute treatment with a specific AMPK activator, 991 4, 20 , promoted TFEB dephosphorylation in the absence of detectable inhibition of mTOR (as judged by phosphorylation of p70 S6K and S6RP) in primary hepatocytes. In a previous study, it has been
shown that phosphorylation of TFEB at S142 represents a Rapamycin-resistant, but Torinsensitive site 48 . In line with this, we observed that the S142 phosphorylation was not affected by Rapamycin. However, in contrast to the previous observation, Torin displayed only a marginal effect on TFEB dephosphorylation (i.e. appearance of a minor faster-migrating form of the total TFEB and reduced S142 phosphorylation), and notably this was not only observed in WT, but also in AMPK KO MEF. Collectively, in MEF and primary hepatocytes, 1) we have demonstrated that acute inhibition of mTOR (i.e. 1-4 hours) does not modulate TFEB phosphorylation, and 2) 991-induced dephosphorylation of TFEB is unlikely to be mediated through AMPK-dependent suppression of mTOR. However, it would be important to assess if other phosphorylation sites (e.g. S211, S138), which are proposed to play key roles for cellular distribution of TFEB 62 , are regulated upon AMPK activation.
The mechanism by which AMPK dephosphorylates and activates TFEB is unknown. It has been demonstrated that nutrient deprivation induces the release of lysosomal Ca 2+ through Ca 2+ channel mucolipin 1. This activates calcium/calmodulin-activated serine/threonine phosphatase calcineurin (also known as protein phosphatase 2B), which binds to and dephosphorylates TFEB, thus promoting its nuclear localization and autophagy induction 63 . It would be interesting to determine if AMPK-mediated activation of TFEB regulates the catalytic activity of calcineurin and/or interaction between TFEB and calcineurin. It has also been shown that nutrient/glucose deprivation-induced AMPK activation regulates lysosomal and autophagy gene expression through phosphorylation at S659 and nuclear localization of acetyl-CoA synthetase 2 (ACSS2) 64 . Phosphorylated ACSS2 forms a complex with TFEB, which modulates lysosomal and autophagosomal genes by locally producing acetyl CoA for histone H3 acetylation in the promoter regions of these genes. Therefore, AMPK indirectly modulates the transcriptional activity of TFEB after its nuclear translocation via inhibition of mTOR in response to energy stress. Nonetheless, in the current study we found Acss2 as one of the AMPK-dependent genes upregulated at mRNA levels in response to both 991 and AICAR.
Whether this upregulation of Acss2 is linked to an increase in its protein/phosphorylation levels needs to be determined.
Although TFEB is an established master regulator of lysosomal biogenesis 65, 66 , emerging evidence suggests that it also acts as key controller for various other cellular and metabolic responses, including lipid metabolism in liver 67 , mitochondrial biogenesis in muscle 44 , as well as modulation of the immune response 68 . In summary, we demonstrated in fibroblasts, hepatocytes, as well as at whole organism levels, in vivo using zebrafish, that pharmacological/physiological activation of AMPK promoted nuclear translocation of TFEB. This appeared to be through an apparent effect on dephosphorylation of TFEB, independent of mTOR, and was associated with induction of a tumor suppressor FLCN through activation of its promoter activity. Future studies using gain of function models of FLCN in skeletal muscle and other tissues (e.g. liver) could reveal the physiological significance of the AMPK-TFEB-FLCN pathway.
MATERIALS AND METHODS
Materials
The 
Cell culture
Mouse embryonic fibroblasts (MEF) from wild-type (WT) and AMPK α1
-/-/α2 -/-mice were generated as described previously 70 . TFEB -/-/TFE3 -/-MEF were a kind gift from Rosa Puertollano (NIH). MEF were cultured in DMEM-Glutamax supplemented with 10% fetal calf serum (FCS) and 1% penicillin streptomycin. Cells were seeded at ~80% confluency and treated the following day at the indicated treatments described in the figures. Cells were washed with ice-cold PBS and scraped into lysis buffer (50 mM HEPES, 150 mM NaCl, 100 mM NaF, 10 mM Na-pyrophosphate, 5 mM EDTA, 250 mM sucrose, 1 mM DTT, 1% Triton X-100, 1 mM Na-orthovanadate, 0.5 mM PMSF, 1 mM benzamidine HCl, 1 µg/ml leupeptin, 1 µg/ml pepstatin-A, 1 mM microcystin-LR). Primary hepatocytes were isolated AMPKα1/α2 liverspecific knockout mice and control AMPKα1 lox/lox α2 lox/lox mice littermates (10-week-old males)
by collagenase perfusion and cultured as previously described 35 . The experiments were performed accordingly with the European guidelines (approved by the French authorisation to experiment on vertebrates (no. 75-886) and the ethics committee from University Paris Descartes (no. CEEA34.BV.157.12). Briefly the cells were plated in M199 medium containing Glutamax and supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 10% (v/v) FBS, 500 nM dexamethasone (Sigma), 100 nM triiodothyronine (Sigma), and 10 nM insulin (Sigma).
The hepatocytes were allowed to attach (4 hours), and were then maintained in M199 medium 
RNA extraction, microarray and bioinformatic analysis
Total RNA was extracted from cells using RNAdvance Tissue Kit (A32645; Beckman Coulter) and quantified by RiboGreen (R11490; ThermoFisher). RNA integrity was determined by 
RT-qPCR
For cDNA synthesis, 500 ng of total RNA was used as starting material for the PrimeScript RT Kit (Takara, #RR037A). RT-qPCR reactions were performed on a LightCycler 480 with SYBR Green Assay (Roche, #04707516001), with primers at a final concentration of 0.3 µM/reaction.
All the primers used in this study are summarized with sequences in Supplementary Table 2 .
For mouse samples, three normalization genes were used, namely Acyl-CoA synthetase shortchain (Acss), β2 microglobulin (B2m), Peptidylprolyl isomerase-a (Ppia), and their stability was assessed using GeNorm (M value < 0.6) 71, 72 . For zebrafish samples, two normalization genes were used, being elongation factor 1-α (ef1a) and nuclear respiratory factor 1 (nrf1).
Normalized values were calculated by dividing the average expression value by a factor equal to the geometric mean of the normalization genes 71 .
The relative Flcn mRNA quantity of the samples used in Fig. 3D was assessed using a Biomark gene expression 192.24 IFC delta gene assay, Fluidigm Biomark, following manufacturer's instruction. Ct values were calculated using the system's software (Biomark Real-time PCR analysis, Fluidigm). For the analysis, two normalization genes were used (Ppia and TATA boxbinding protein (Tbp)), afterwards two-way ANOVA was fit to the log-transformed data.
Generation of actc1b:tfeb-ZsGreen; actc1b:nls-mCherry double transgenic fish
Adult AB zebrafish were raised at 28°C under standard husbandry conditions. All experimental procedures were carried out according to the Swiss and EU ethical guidelines and were approved by the animal experimentation ethical committee of Canton of Vaud (permit VD3177). Transgenic zebrafish Tg(actc1b:tfeb-ZsGreen) nei08 and Tg(actc1b:nls-mCherry) nei09 were independently generated using I-SCEI meganuclease mediated transgenic insertion into one-cell stage embryos as previously described 73 . One founder for each transgenic line was selected and subsequent generations were propagated and expanded. The two lines were crossed to generate double transgenic embryos, which have been raised at 28°C under standard laboratory conditions before treatment. Double transgenic embryos were selected at 3 dpf and treated with 991 10 µM or DMSO in 96 well plates (n=12). After 24 h of treatment embryos were anesthetized with 0.016% tricaine and imaged with ImageXpress confocal system at 20X magnification (Molecular Devices). Z stack images were captured for each embryo and maximal projection images were produced.
Generation of prkaa1 -/-;prkaa2 -/-double knockout fish
The prkaa1
-/-;prkaa2 -/-double knockout fish were generated by using the CRISPR/Cas9 approach (manuscript in preparation). Two gRNA targeting prkaa1 exon 5 and prkaa2 exon 6
were designed using the Chopchop online tool (http://chopchop.cbu.uib.no/index.php) and ordered as DNA gene strings. After PCR amplification and purification, they were used as input for in vitro transcription with the MEGAshortscript T7 Kit (Thermo Fisher Scientific). BSA overnight at 4°C.
Cloning and mutagenesis
All plasmid constructs were generated using standard molecular biology techniques. The promoter sequences and the TFEB/3 binding site were identified from the EPD promoter database (https://epd.vital-it.ch/index.php). The promoter regions were amplified from mouse genomic DNA (Promega), then ligated into a modified pNL 1.2 luciferase vector (Promega).
The luciferase assay was carried out according to the company's protocol (Promega).
To express transiently the mouse TFEB cDNA, the clone MR223016 was ordered from
Origene. The phospho sites corresponding to human S122, S142 and S211 were mutated to alanine using standard molecular biology methods. The sequences of all constructs were verified in house utilizing the BigDyeR Terminator 3.1 kit and the 3500XL Genetic analyzer (ABI-Invitrogen).
Statistical analysis
For the statistical analysis, two-way ANOVA with interaction was used to analyze the data or was fit to the log-transformed data, as specified in the figure legend. Data are expressed as boxand-whisker plot (min to max), log2 fold-change of the mean ± SEM or SD, as indicated.
Differences between groups were considered statistically significant when P-value < 0.05.
Accession numbers
The microarray data were deposited in GEO, the accession number will be publicly available once the article is accepted. were subjected to western blot analysis using the indicated antibodies (n=2). Laemmli extracts (20 μg) were subjected to western blot analysis using the indicated antibodies. 
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